CRBP Stock Analysis: Corbus Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 171m USD | 12M Return: 28.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.19M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) is a U.S.-based, clinical-stage biotechnology company that develops therapeutics for cancer and obesity. Founded in 2009 and headquartered in Norwood, Massachusetts, the company went public in November 2014 and currently trades with a micro-cap market capitalization.
The companys pipeline is led by CRB-701, an antibody drug conjugate (ADC) targeting Nectin-4-expressing cancer cells and delivering the cytotoxic payload monomethyl auristatin E (MMAE), and CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist aimed at treating obesity. As a clinical-stage biotech, Corbus generates no commercial product revenue and depends on capital markets and potential partnerships to fund ongoing R&D and clinical trials.
- CRB-701 Phase 1 oncology data readout in Nectin-4 tumors
- CRB-913 obesity candidate faces GLP-1 competitive pressure
- Cash burn forces dilutive equity offering to extend runway
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.51 > 0.02 and ΔFCF/TA -15.07 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.51 > 3% & CFO -73.6m > Net Income -84.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.3m) vs 12m ago 9.14% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.50%; Δ -0.50% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 143.6m - Total Current Liabilities 18.1m) / Total Assets 144.5m |
| B: -4.00 (Retained Earnings -578.4m / Total Assets 144.5m) |
| C: -0.59 (EBIT TTM -84.5m / Avg Total Assets 142.2m) |
| D: 6.97 (Book Value of Equity 126.3m / Total Liabilities 18.1m) |
| Altman-Z'' = -4.04 = D |
As of July 08, 2026, the stock is trading at USD 9.38 with a total of 528,761 shares traded. Over the past week, the price has changed by +4.45%, over one month by +24.07%, over three months by -3.40% and over the past year by +28.49%.
Current recommended Stop Loss: 8.70 (which is 7.2% or 1.2 ATR below the current price).
Corbus Pharmaceuticals has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy CRBP.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.3 | 276.3% |
P/S = 169.8824
P/B = 1.3301
Revenue TTM = 0.0 USD
EBIT TTM = -84.5m USD
EBITDA TTM = -84.3m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.21m USD (from shortTermDebt, last quarter)
Debt = 1.21m USD (from shortLongTermDebtTotal, last quarter) (leases 1.21m already included)
Net Debt = -137.4m USD (calculated: Debt 1.21m - CCE 138.6m)
Enterprise Value = 34.0m USD (171.4m + Debt 1.21m - CCE 138.6m)
Interest Coverage Ratio = unknown (Ebit TTM -84.5m / Interest Expense TTM 0.0)
EV/FCF = -0.46x (Enterprise Value 34.0m / FCF TTM -73.7m)
FCF Yield = -216.7% (FCF TTM -73.7m / Enterprise Value 34.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 233k) / Revenue TTM)
Tobins Q-Ratio = 0.24 (Enterprise Value 34.0m / Total Assets 144.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.21m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -66.8m (EBIT -84.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.92 (Total Current Assets 143.6m / Total Current Liabilities 18.1m)
Debt / Equity = 0.01 (Debt 1.21m / totalStockholderEquity, last quarter 126.3m)
Debt / EBITDA = 1.63 (negative EBITDA) (Net Debt -137.4m / EBITDA -84.3m)
Debt / FCF = 1.87 (negative FCF - burning cash) (Net Debt -137.4m / FCF TTM -73.7m)
Total Stockholder Equity = 119.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.44% (Net Income -84.5m / Total Assets 144.5m)
RoE = -70.89% (Net Income TTM -84.5m / Total Stockholder Equity 119.2m)
RoCE = -70.89% (EBIT -84.5m / Capital Employed (Equity 119.2m + L.T.Debt 0.0))
RoIC = -52.35% (negative operating profit) (NOPAT -66.8m / Invested Capital 127.5m)
WACC = 10.56% (E(171.4m)/V(172.6m) * Re(10.63%) + D(1.21m)/V(172.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.06 | Cagr: 99.87%
[DCF] Fair Price = unknown (Cash Flow -73.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.03 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.24 | Chg30d=-0.02% | Revisions=-50% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-1.03 | Chg30d=-0.94% | Revisions=-10% | Analysts=10
EPS current Year (2026-12-31): EPS=-4.57 | Chg30d=-1.35% | Revisions=+0% | GrowthEPS=+22.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.08 | Chg30d=+0.59% | Revisions=-36% | GrowthEPS=-11.2% | GrowthRev=+116.0%
[Analyst] Revisions Ratio: -28% (up=9, down=17)